San Antonio Breast Cancer Symposium
The model uses clinical and genomic features to predict whether patients will respond to first-line CDK4/6 and endocrine therapy.
Lessons from the Phase III ZEST trial could inform ongoing and future trials as they seek to use ctDNA to prove efficacy of novel adjuvant treatments.
Ibrance Plus Frontline Standard Therapy Delays Progression in HER2, HR-Positive Breast Cancer
Premium
Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.
Data from Myriad Genetics offered early validation evidence for an expanded version of its commercial test, as well as a look into clinical impact via claims data.
SABCS Studies Highlight Novel HER2 Therapies in Frontline Setting, HER2-Low, Brain Metastases
Premium
Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.